| Pharmaceutical Information |
| Drug Name |
Efinaconazole |
| Drug ID |
BADD_D00750 |
| Description |
Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. |
| Indications and Usage |
Indicated in the treatment of fungal infection of the nail, known as onychomycosis. |
| Marketing Status |
approved |
| ATC Code |
D01AC19 |
| DrugBank ID |
DB09040
|
| KEGG ID |
D10021
|
| MeSH ID |
C431707
|
| PubChem ID |
489181
|
| TTD Drug ID |
D0G4BI
|
| NDC Product Code |
46438-0644; 76397-018; 65015-896; 66039-930; 46016-1642; 66064-1024; 68259-1314; 70600-001; 51686-0012; 76397-017; 0187-5400; 51265-541; 51557-001; 76397-006; 58175-0606 |
| UNII |
J82SB7FXWB
|
| Synonyms |
efinaconazole | KP 103 | KP103 | KP-103 | Jublia |
|
| Chemical Information |
| Molecular Formula |
C18H22F2N4O |
| CAS Registry Number |
164650-44-6 |
| SMILES |
CC(C(CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
